Phase III, Randomized, Double-Blind, Placebo-Controlled

Project: Research project

Project Details

Description

Phase III, Randomized, Double-Blind, Placebo-Controlled Study of SU011248 in the Treatment of Patients with Imatinib Mesylate (Gleevec, Glivec)-Resistant or Intolerant
StatusFinished
Effective start/end date9/19/038/31/10

Funding

  • SUGEN INC

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.